10.04.2013 - In a thorough comparison, Lundbeck's new antidepressant Brintellix shone brightly: On a system for rating depression patients performed better.
Danish H. Lundbeck A/S reported on positive results for the REVIVE study, a double-blind randomised study of Brintellix (vortioxetine) in adults with major depressive disorder (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment. In this study, the objective was to compare the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus Servier's agomelatine (25-50mg/day) in this challenging MDD patient population. "Patients with inadequate response to current SSRI or SNRI therapies represent a large proportion of patients suffering from major depression. Only a few years ago, the landmark STAR*D study1 confirmed a significant unmet medical need, as only half of patients responded to their first-line treatment, which was an SSRI," said Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck. The US-American FDA accepted an NDA from Lundbeck and its partner Takeda on Brintellix last December.
Brintellix is under investigation as a multimodal antidepressant thought to work through a combination of two complementary mechanisms of action: receptor activity modulation and reuptake inhibition. In vivo non-clinical studies have demonstrated that Brintellix modulates neuronal firing and neurotransmitter release in multiple systems, resulting in enhanced levels of serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the brain. The multimodal activity profile of Brintellix is different from the profile of currently anti-depressive medicines.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.